Education
About Us
Working with TipRanks
Follow Us
XLV - ETF AI Analysis
Top Page
Health Care Select Sector SPDR Fund (XLV)
Rating:73Outperform
Price Target:
$161.00
Positive Factors
Strong Top Holdings
Several top holdings, such as Johnson & Johnson, AbbVie, and Gilead Sciences, have shown strong year-to-date performance, supporting the ETF's overall returns.
Low Expense Ratio
The ETF has a very low expense ratio compared to industry averages, making it a cost-effective choice for investors.
Focused Sector Exposure
The ETF's concentration in the health care sector provides targeted exposure to a historically resilient and essential industry.
Negative Factors
Over-Concentration in Health Care
The fund is heavily concentrated in a single sector, which limits diversification and increases vulnerability to sector-specific risks.
Underperforming Holdings
Some key holdings, such as UnitedHealth and Merck, have shown weak year-to-date performance, which could drag on overall returns.
Limited Geographic Diversification
With nearly all of its exposure in U.S. companies, the ETF lacks international diversification, which could be a disadvantage during global market shifts.
XLV vs. SPDR S&P 500 ETF (SPY)
AUM36.87B
RegionNorth America
Expense Ratio0.08%
Beta0.53
IssuerSPDR
Inception DateDec 16, 1998
Dividend Yield1.68%
Asset ClassEquity
Index TrackedS&P Health Care Select Sector
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,681,011
30 Day Avg. Volume12,536,253
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
163.53Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering62
XLV Summary
The Health Care Select Sector SPDR Fund (XLV) is an ETF that focuses on the healthcare sector, tracking the S&P Health Care Select Sector Index. It includes companies from industries like pharmaceuticals, biotechnology, and medical devices. Some of its top holdings are well-known names like Johnson & Johnson and Merck. Investors might consider XLV for its potential growth and stability, as healthcare is essential and often resilient during economic downturns. However, new investors should be aware that its performance is closely tied to the healthcare sector, which can be affected by regulatory changes or industry-specific challenges.
How much will it cost me?The Health Care Select Sector SPDR Fund (XLV) has an expense ratio of 0.08%, meaning you’ll pay $0.80 per year for every $1,000 invested. This cost is lower than average because XLV is passively managed, tracking the Health Care Select Sector Index rather than relying on active stock picking.
What would affect this ETF?The XLV ETF, focused on the U.S. healthcare sector, could benefit from increasing demand for healthcare services driven by aging populations and advancements in medical technology. However, it may face challenges from regulatory changes, drug pricing pressures, or economic downturns that could impact healthcare spending. Its exposure to major companies like Johnson & Johnson and Pfizer provides stability but also ties its performance to the success of these key players.
XLV Top 10 Holdings
The Health Care Select Sector SPDR Fund (XLV) is leaning heavily on pharmaceutical and biotech giants to drive performance, with Eli Lilly and Johnson & Johnson leading the charge thanks to rising momentum and strong earnings. AbbVie and Thermo Fisher are also steady contributors, buoyed by strategic investments and operational strength. However, UnitedHealth and Intuitive Surgical are holding the fund back, with UnitedHealth facing cost pressures and Intuitive Surgical grappling with mixed technical signals. With nearly all holdings rooted in the U.S. healthcare sector, XLV offers a concentrated play on innovation and resilience in this critical industry.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.37% | $4.57B | $776.19B | -9.24% | 70 Outperform | |
| Johnson & Johnson | 8.63% | $3.19B | $450.37B | 16.76% | 78 Outperform | |
| AbbVie | 7.58% | $2.80B | $401.96B | 20.10% | 64 Neutral | |
| UnitedHealth | 6.24% | $2.30B | $333.14B | -34.56% | 73 Outperform | |
| Abbott Laboratories | 4.17% | $1.54B | $220.36B | 11.65% | 77 Outperform | |
| Merck & Company | 4.14% | $1.53B | $217.38B | -16.10% | 76 Outperform | |
| Thermo Fisher | 4.01% | $1.48B | $210.57B | 1.80% | 73 Outperform | |
| Intuitive Surgical | 3.72% | $1.37B | $193.34B | 5.63% | 78 Outperform | |
| Amgen | 2.95% | $1.09B | $157.25B | -7.57% | 70 Outperform | |
| Boston Scientific | 2.86% | $1.05B | $149.61B | 19.41% | 77 Outperform |
XLV Technical Analysis
Positive
―
Price Trends
139.83
Positive
136.54
Positive
137.96
Positive
Market Momentum
1.73
Positive
56.14
Neutral
72.23
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XLV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 144.17, equal to the 50-day MA of 139.83, and equal to the 200-day MA of 137.96, indicating a neutral trend. The MACD of 1.73 indicates Positive momentum. The RSI at 56.14 is Neutral, neither overbought nor oversold. The STOCH value of 72.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XLV.
XLV Peer Comparison
Comparison Results
Performance Comparison
XLV
Health Care Select Sector SPDR Fund
143.98
-1.54
-1.06%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
XLF
Financial Select Sector SPDR Fund
―
―
―
VNQ
Vanguard Real Estate ETF
―
―
―
VHT
Vanguard Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents